A few new drug therapies could be on the horizon for some of the most common women’s health infections – vulvovaginal candidiasis and bacterial vaginosis – after years of efforts by the US Food and Drug to incentivize and guide development of new drugs.
Scynexis Inc. touts a “clear regulatory path with high chance of technical success” of ibrexafungerp in vulvovaginal candidiasis (VVC),...




